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Airborne precautions are required at hospital admission for patients with suspected pulmonary tuber-
culosis. The isolation is maintained until 3 serially collected sputum smears are acid-fast bacilli negative,
a time- and labor-intensive method with limited sensitivity and speciﬁcity, which has a great impact on
patient ﬂow management. We evaluated the possibility of replacing the result of microscopy by the
semiquantitative result of the molecular point-of-care test Xpert MTB/RIF to assess patients' transmission
risk to quickly guide airborne isolation decisions in low-endemic countries. The performance of the Xpert
MTB/RIF, used as a ﬁrst-line test, was compared to the results of microscopy for specimens (n¼ 242)
collected from May 2010 to December 2014 in Lausanne, Switzerland. The sensitivity and speciﬁcity of
Xpert MTB/RIF were 91.5% (65/71) and 99.6% (170/171), respectively, vs. 64.8% (46/71) and 94.2% (161/
171) for microscopy. Samples with negative Xpert MTB/RIF were all smear negative for Mycobacterium
tuberculosis (negative predictive value, 100%). The semiquantitative results of Xpert MTB/RIFdhigh,
medium, low or very lowdwere found to correlate with acid-fast bacilli detection: positive predictive
value of 100% (6/6), 96.5% (27/28), 52.2% (12/23) and 11.1% (1/9) respectively. Finally, when including
clinical criteria, we identiﬁed 11 smear-negative but Xpert MTB/RIFepositive patients with a signiﬁcant
transmission potential. In conclusion, our data support the introduction of an Xpert MTB/RIFebased
strategy as a replacement of smear microscopy for a faster and more accurate management of tuber-
culosis patients' transmission risk in a low-prevalence country. O. Opota, CMI 2016;22:613
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Among the prerequisites to limit the worldwide spreading of
tuberculosis, rapid diagnosis of the disease is paramount to allow
the rapid introduction of an efﬁcient antituberculosis treatment, to
take adequate isolation precautions and to achieve contact tracing.
Tuberculosis diagnosis has been dominated for a long time by mi-
croscopy examination of sputum smears for the detection of acid-
fast bacilli (AFB) and by speciﬁc mycobacterial culture. Despite itsobiology, University Hospital
Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).limited sensitivity and speciﬁcity, smear microscopy is historically
the ﬁrst microbial analysis performed when the clinical presenta-
tion of the patient is compatible with pulmonary tuberculosis and
culture results are not yet available (delay of up to 6e8 weeks).
PCR-based methods developed over the last decades have
signiﬁcantly improved and accelerated tuberculosis diagnosis;
however, such methods require a speciﬁc molecular diagnostic
laboratory setup. The need for simpler PCR systems has been solved
with the real-time PCR-based system Xpert MTB/RIF (Cepheid,
Sunnyvale, CA, USA), a simple point-of-care test (POCT) that can
simultaneously detect, in 2 hours, Mycobacterium tuberculosis and
the main mutations associated with resistance to rifampicin. Since
2013, the World Health Organization has recommended the Xpert
MTB/RIF as the initial test for tuberculosis microbial diagnosis forof Clinical Microbiology and Infectious Diseases. This is an open access article under
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cases; for retreatment cases; for suspected multidrug-resistant
(MDR) tuberculosis; and for HIV-infected patients with suspected
tuberculosis because of its excellent sensitivity and speciﬁcity
associated with an extremely short turnaround time [1,2]. At pre-
sent, more than 108 countries (mainly countries endemic for
tuberculosis) are routinely using this diagnostic test [3].
Studies addressing the added value of this rapid molecular test
to assess patients' transmission risk and to guide airborne isolation
decisions are needed. Historically, patients' infectiousness was
addressed by smear microscopy; a positive smear result reinforced
the suspicion of tuberculosis and was associated with a high
transmission risk [4e8]. However, in a low-prevalence setting,
patients with suspected tuberculosis are placed in an isolation
room until three consecutive sputum smears are AFB negative
because of the limited sensitivity of this method. Such a strategy
can have a great impact on patient placement and can result in
unnecessary prolonged stays in isolation rooms [9e11]. A signiﬁ-
cant reduction of the transmission risk of smear-negative patients
compared to smear-positive patients has been observed (relative
risk, 0.28 and 0.47, respectively) [12,13]. Nevertheless, several
studies have demonstrated that tuberculosis transmission can
occur from smear-negative patients, with a minimum relative
transmission rate estimated to 0.22 [14e17]. Thus, smear exami-
nation has a limited sensitivity and speciﬁcity for tuberculosis
diagnosis; it is time and labor intensive, with a great impact on
laboratory routine work ﬂow; further, it requires skilled lab tech-
nicians, and therefore it signiﬁcantly disrupts laboratory routine
work ﬂow. In addition, it cannot distinguish between non-tuber-
culosis mycobacteria and M. tuberculosis, leading to unnecessary
airborne precautions, and it is unable to detect all infectious
patients.
In this study, we aimed to determine the potential added value
of the Xpert MTB/RIF PCR to address patients' transmission po-
tential in a faster, more accurate and more reliable manner in low-
prevalence settings.
Materials and Methods
Study design
The tuberculosis diagnostic laboratory of the Institute of
Microbiology is part of the Lausanne University Hospital, a 1000-
bed tertiary-care hospital located in Switzerland, a low-
tuberculosis-prevalence country (approximately six new cases per
year per 100 000 population; Swiss Federal Ofﬁce of Public Health
(FOPH), http://www.bag.admin.ch/). Our laboratory processes
approximately 3500 samples for pulmonary tuberculosis suspicion
per year. Each year, approximately 50 new cases of tuberculosis are
conﬁrmed by culture. Until 2010, the diagnosis of pulmonary
tuberculosis relied on smear microscopy, on an in-house TaqMan
probeebased real-time PCR [18] and on mycobacterial culture.
In May 2010, the Xpert MTB/RIF assay was implemented in our
laboratory. We retrospectively compared the results of the Xpert
MTB/RIF, smear microscopy and mycobacterial culture on respira-
tory samples collected in patients with suspected pulmonary
tuberculosis from May 2010 to December 2014. During this study
period, 4918 patients (11 414 samples) were tested for suspected
pulmonary tuberculosis. Only samples for which these three ana-
lyses were available were included in the study. Indeed, while
smear microscopy and culture are systematically performed for
suspected pulmonary tuberculosis, the Xpert MTB/RIF was selec-
tively requested by clinicians for patients with a high pretest
probability of disease on the basis of clinical and epidemiologic
data, or for patients with suspected infection with MDRtuberculosis, as recommended by the World Health Organization
[1]. When multiple samples were available for a given patient, only
the ﬁrst sample was considered. As a consequence, our study is
made up of spot samples collected at hospital presentation rather
than of morning samples. All data were extracted from our labo-
ratory database. Clinical reviews were extracted from the software
of our hospital.
The study was approved by the local ethics committee (Com-
mission Cantonale d'Ethique de la Recherche sur l'Etre Humain,
Lausanne, Switzerland).
Microbiologic diagnosis of tuberculosis
All the microbial analyses were performed on the same sample
after splitting it for AFB staining, Xpert MTB/RIF analysis and
mycobacterial culture. AFB detection was achieved through a
ﬂuorescent auramine-Thiazine Red staining on a heat-ﬁxed smear.
After heat ﬁxation on a slide, the sample was placed in a staining
rack containing the 0.1% auramine staining solution for 15 minutes.
After rinsing with tap water, the sample was treated with the 0.5%
acidealcohol decolourizing solution for 5 minutes and again rinsed
with tap water. Counterstaining was achieved with Thiazine Red
applied for 3 minutes. After a ﬁnal rinse in tap water, the slides
were dried and observed by ﬂuorescent microscopy.
Smear grading was determined according to the International
Union Against Tuberculosis and Lung Disease scale [19]. The
staining was performed on nondecontaminated respiratory sam-
ples. Purulent sputum or bronchial aspirates were solubilized with
the mucolytic agent N-acetyl-L-cysteine (2% m/v pH 6.8) to increase
the homogeneity of the sample before smear preparation. Samples
with a volume exceeding 3mL were concentrated by centrifugation
(30 minutes, 3000  g). Mycobacterial culture was performed in a
Mycobacteria Growth Indicator Tube (Becton Dickinson, Heidel-
berg, Germany) after sample decontamination using a solution
containing N-acetyl-L-cysteine (2% m/v) and with NaOH (2% m/v)
[20]. The Xpert MTB/RIF analysis was performed on non-
decontaminated samples according to the manufacturer's in-
structions. When positive, the Xpert MTB/RIF provides a
semiquantitative result deﬁned by the manufacturer as follows:
positiveevery low (cycle threshold (Ct) >28), low (Ct 22e28), me-
dium (Ct 16e22) or high (Ct <16).
Statistical comparison between semiquantitative Xpert MTB/RIF
method and smear microscopy
The diagnostic performance of the Xpert MTB/RIF was
compared to that of smear microscopy, with the reference standard
being mycobacterial culture. The sensitivity, speciﬁcity, negative
predictive value (NPV), positive predictive value (PPV) and 95%
conﬁdence intervals were calculated by GraphPad Prism 6.00 for
Windows (GraphPad Software, La Jolla, CA, USA). The correlation
between these two diagnostic methods was determined, and the
clinical characteristics of patients with discrepant results were
reviewed.
Results
Patients and samples
Our study included respiratory specimens collected from 252
patients with suspected pulmonary tuberculosis. Specimens
collected after the initiation of an antituberculosis treatment
(n¼ 10) were excluded from our analysis because of the possible
decrease in culture sensitivity (Fig. 1). Thus, a total of 242 samples
from 242 patients were studied. Of these 242 samples, 71 (29.3%,
Fig. 1. Study design and sample distribution.
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242) were culture negative. This high rate of culture-conﬁrmed
positive patients is because during the period of the study, the
Xpert MTB/RIF wasmainly dedicated to patients with a high pretest
probability of pulmonary tuberculosis. Among the 71 specimens
with positiveM. tuberculosis, 46 (64.7%, 46/71) were smear positive.
Among the 171 specimens with negativeM. tuberculosis culture, 10
(6%, 10/171) were smear positive: eight of them grew non-tuber-
culosismycobacteria (NTM), whereas the two remainingwere false-
positive smear results due to ﬂuorescent artefacts.
Sensitivity, speciﬁcity and predictive value of Xpert MTB/RIF and
smear microscopy using M. tuberculosis culture as reference
standard for active pulmonary tuberculosis
We ﬁrst established the performance of Xpert MTB/RIF and
smear microscopy in the setting of our hospital (Table 1). Using
M. tuberculosis culture as the reference standard for active pulmo-
nary tuberculosis, the sensitivity and speciﬁcity of the Xpert MTB/
RIF were 91.5% (65/71) and 99.4% (170/171), respectively, corre-
sponding to a PPV of 98.5% (65/66) and a NPV of 96.6% (170/176).
This was signiﬁcantly higher than the sensitivity and speciﬁcity of
smear examination, which were 64.7% (46/71) and 94.2% (161/171),
respectively, corresponding to a PPV of 82.1% (46/56) and a NPV of
86.6% (171/186) (Table 1). A single sample tested positive by Xpert
MTB/RIF but negative by M. tuberculosis culture. This sample was
from a bronchial aspirate from a patient who presented with
dyspnoea, cough and chest pain. Similarly, the bronchoalveolar
lavage sample of the same patient was Xpert MTB/RIF positive and
culture negative. Computed tomographic scan revealed the pres-
ence of a pulmonary condensation with cavitation. An antituber-
culosis treatment for active pulmonary tuberculosis was initiated
by clinicians.Correlation between Xpert MTB/RIF semiquantitative results and
smear microscopy results
We next decided to investigate the correlation between the
semiquantitative results of Xpert MTB/RIF and smear microscopy.
We ﬁrst found that all the samples with smear examination positive
for M. tuberculosis had a positive Xpert MTB/RIF test, which corre-
sponded to an overall sensitivity of the Xpert MTB/RIF to detect
smear-positive samples of 100% (46/46) (Table 2). Conversely
samples with negative Xpert MTB/RIF were all smear negative for
M. tuberculosis (NPV¼ 100%, 166/166). When positive, the Xpert
MTB/RIF provides semiquantitative results deﬁned by the manu-
facturer as follows: positive-very low (Ct >28), low (Ct 22e28),
medium (Ct 16e22) or high (Ct <16). We compared the Xpert MTB/
RIF semiquantitative results to smear grading results (Table 3). All
samples that tested positiveehigh by Xpert MTB/RIF were smear
positive corresponding to a PPV, for a smear positivity of 100% (6/6).
Among samples with positiveemedium Xpert MTB/RIF results, 27
of 28 were smear positive, corresponding to a PPV for smear pos-
itivity of 96.4%. The PPV for smear positivity of samples with pos-
itiveelow and positiveevery low Xpert MTB/RIF results were 55%
(12/23) and 11.1% (1/9), respectively. These data show that the
Xpert MTB/RIF semiquantitative results positively correlate with
smear examination.
Clinical presentation of tuberculosis patients with smear-negative
result and Xpert MTB/RIF positive result
The transmission potential of suspect tuberculosis patients is
generally assessed on the basis of smear examination. Smear-
negative patients are generally considered as less infectious. Our
study identiﬁed 20 patients with positive Xpert MTB/RIF but
negative smear examination. The analysis of the clinical data for
Table 1
Comparison of diagnostic performance
Examination Mycobacterium tuberculosisepositive culture, % (95% CI) for:
Sensitivity Speciﬁcity PPV NPV
Smear microscopy 64.8 (52.5e75.8) 94.2 (89.5e97.2) 82.1 (69.6e91.1) 86.6 (81.0e91.1)
46/71 161/171 46/56 171/186
Xpert MTB/RIF 91.5 (82.5e96.8) 99.4 (96.8e100) 98.5 (91.84e100) 99.6 (92.7e98.7)
65/71 170/171 65/66 170/176
CI, conﬁdence interval; NPV, negative predictive value; PPV, positive predictive value.
Table 2
Detection of smear-positive samples with Xpert MTB/RIFa
Examination Smear positivity detection, % (95% CI) for:
Sensitivity Speciﬁcity PPV NPV
Xpert MTB/RIF 100 (92.3e100) 89.3 (83.9e93.3) 69.7 (57.1e80.4) 100 (97.8e100)
46/46 166/186 46/66 166/166
CI, conﬁdence interval; NPV, negative predictive value; PPV, positive predictive value.
a Smear-positive samples negative forMycobacterium tuberculosis culture, corresponding to samples positive with non-tuberculosismycobacteria or containing ﬂuorescent
artifacts, were excluded from this analysis (n¼ 10).
Table 3
Correlation between Xpert MTB/RIF semiquantitative result and smear microscopy results
Xpert MTB/RIF result Smear microscopy result Prediction of smear positivity
Negative Scanty 1þ 2þ 3þ Total smear positivea Total samples Predictive value of smear positivity (95% CI)
Positiveehigh 1 1 1 3 6 6 PPV 100%
(54.1e100)
Positiveemedium 1 6 14 5 2 27 28 PPV 95.4%
(81.6e99.9)
Positiveelow 11 7 3 2 12 23 PPV 52.2%
(30.6e73.2)
Positiveevery low 8 1 1 9 PPV 11.1%
(0.3e48.2)
Negative 166 8b 2c 0 176 NPV 100%a
(97.8e100)
Total 186 22 21 8 5 46 242
CI, conﬁdence interval; NPV, negative predictive value; NTM, non-tuberculosis mycobacteria; PPV, positive predictive value.
a After exclusion of NTM and mycobacterial-negative samples.
b Mycobacterium tuberculosis culture negative (six NTMs and two samples with one to two acid-fast bacilli).
c M. tuberculosis culture negative (two NTMs).
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symptomatic (cough, sputum, pulmonary inﬁltrate, weight loss,
asthenia; Table 4). Remarkably, among these smear-negative pa-
tients, 11 (55%) of 20 presentedwith pulmonary cavitation, which is
associated with a high transmission potential but would have been
misclassiﬁed as poorly infectious on the basis of an initial negative
smear examination. Finally, among these 11 smear-negative but
Xpert MTB/RIFepositive patients, the molecular test identiﬁed one
patient infected with a MDR isolate (patient 2; Table 4).
Discussion
To date, sputum smear microscopy remains the ﬁrst microbial
analysis both for tuberculosis diagnosis and assessment of patient
infectiousness, which guide airborne isolation measures [3e6,8].
However, smear microscopy is time and labor intensive, requires
specialized technicians and has a limited sensitivity. In addition,
smear microscopy displays limited speciﬁcity because AFB staining
cannot distinguish between M. tuberculosis and non-tuberculosis
mycobacteria.
In most laboratories, sputum smear microscopy is still per-
formed to assess the degree of infectivity of patients, as it is still
considered the microbiologic reference standard when decidingwhether to isolate the patient. This strategy has a great impact on
patient placement and hospital costs, especially in regions with low
tuberculosis prevalence. In the present study, we compared the
performance of the Xpert MTB/RIF to microscopy to determine the
potential added value of the molecular POCT as a ﬁrst-line test for
tuberculosis diagnosis as well as to assess patients' transmission
potential and to decide whether the patient needs to be isolated.
We found that in the setting of our hospital, which is located in a
low-prevalence country, the sensitivity and speciﬁcity of the Xpert
MTB/RIF were higher than the sensitivity and speciﬁcity of smear
microscopy. These results are in line with all the studies conducted
so far that have evaluated the performance of the Xpert MTB/RIF
[2,21,22]. We next compared the semiquantitative result of the
Xpert MTB/RIF with those of conventional microscopy using the
international smear grading system [19] and found that the results
of the Xpert MTB/RIF could be used as a predictor of smear result.
Samples with high, medium, low and very low Xpert MTB/RIF re-
sults corresponded to PPV of smear positivity of 100%, 96.5%, 52.2%
and 11.1%, respectively. In addition, we reported that all cases with a
negative Xpert MTB/RIF result corresponded to negative smear
examination (NPV¼ 100%). Finally, we observed that 55% of
tuberculosis patients with negative smear microscopy but positive
Xpert MTB/RIF results had a clinical presentation suggestive of high
Table 4
Clinical presentation of patients with positive Xpert MTB/RIF result and negative smear examination
Patient
no.
Sex, age
(years)
Specimen source Smear result MTBCGX rpoB Xpert
MTB/RIF
Mycobacterium
tuberculosis
culture
Cavitation Radiologic ﬁndings Clinical presentation
1 F, 20 Sputum Negative Positive medium Negative Positive Yes Lung inﬁltrate with cavitation Cough, weight loss
2 M, 19 Induced sputum Negative Positive low Positive Positive Yes Lung inﬁltrate with cavitation No symptoms
3 F, 20 Sputum Negative Positive low Negative Positive Yes Lung inﬁltrate with cavitation Cough, weight loss,
HIV infection, pregnancy
4 M, 23 Sputum Negative Positive Low Negative Positive Yes Lung inﬁltrate with cavitation Cough, haemoptysis,
weight loss, HIV infection
5 M, 38 Bronchial aspirate Negative Positive low Negative Positive Yes Lung inﬁltrate with cavitation No symptoms
6 M, 36 Sputum Negative Positive Low Negative Positive Yes Miliary lung inﬁltrate with
cavitation
Cough, weight loss,
asthenia, fever,
immunosuppressive
therapy (inﬂiximab)
7 M, 33 Bronchial aspirate Negative Positive low Negative Positive No Miliary lung inﬁltrate Cough, haemoptysis,
weight loss, HIV infection
8 F, 47 Bronchial aspirate Negative Positive low Negative Positive No Miliary lung inﬁltrate Weight loss, asthenia
9 M, 49 Bronchial aspirate Negative Positive low Negative Positive No Lung inﬁltrate HIV infection, lymphoma
10 M, 50 Induced sputum Negative Positive low Negative Positive NA NA NA
11 F, 39 Induced sputum Negative Positive low Invalid Positive NA NA NA
12 M, 21 Bronchial aspirate Negative Positive very low Negative Positive Yes Lung inﬁltrate with cavitation Cough
13 M, 27 Sputum Negative Positive very low Negative Positive Yes Lung inﬁltrate with cavitation Cough, haemoptysis,
weight loss
14 M, 33 Induced sputum Negative Positive very low Invalid Positive Yes Lung inﬁltrate with cavitation Cough, weight loss
15 F, 26 Bronchial aspiration Negative Positive very low Negative Positive Yes Lung inﬁltrate with cavitation Cough, haemoptysis
16 M, 44 Bronchial aspiration Negative Positive very low Negative Negative Yes Lung inﬁltrate with cavitation Cough, weight loss,
asthenia
17 M, 37 Sputum Negative Positive very low Negative Positive No Lung inﬁltrate with pleural
effusion
Cough, HIV infection
18 M, 46 Bronchial aspirate Negative Positive very low Negative Positive No Lung inﬁltrate Cough, haemoptysis,
weight loss, asthenia
19 M, 47 Sputum Negative Positive very low Negative Positive No Lung inﬁltrate Weight loss, asthenia
20 F, 36 Sputum Negative Positive very low Negative Positive NA NA NA
NA, not available.
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lower than ten bacilli, whereas microscopy sensitivity ranges from
5000 to 10 000 AFB/mL, suggesting that microscopy would miss
many potentially infectious patients.
Our results suggest an added value of the Xpert MTB/RIF
compared to smear microscopy to assess the transmission potential
of tuberculosis patients because when negative, the smear micro-
scopy will be negative too, conﬁrming the rather low risk of
contagiousness of the patient; and when positive, the semi-
quantitative result of the Xpert MTB/RIF can be used to distinguish
patients with a deﬁnitively high risk of being contagious (when
Xpert MTB/RIF is positive-high or medium) from those who are less
contagious (when Xpert MTB/RIF is positive-low or very low). Our
study identiﬁed sixM. tuberculosis culture-conﬁrmed patients with
initial negative Xpert MTB/RIF. These patients had also an initial
negative smear examination; interestingly, none of the consecutive
smear examination of these patients was positive. Future studies
including a larger number of samples and patients should conﬁrm
that a single negative PCR-based assay is synonymous to three
negative smear examinations.
Smear status has historically been the initial microbiology test
to address patients' infectiousness and was also used to aid health
care decisions regarding patient isolation as well as contact in-
vestigations [5,7,8]. Relying on the correlation between the
semiquantitative results of the Xpert MTB/RIF and smear micro-
scopy results, our study supports the use of the molecular POCT
both to initiate tuberculosis diagnosis and to assess patients'
transmission potential, as patients with negative Xpert MTB/RIF
can be considered not infectious or poorly infectious and do not
warrant speciﬁc airborne isolation, whereas patients with positive
Xpert MTB/RIF should be considered as potentially infectious, and
thus airborne isolation should be maintained or immediately
introduced if not yet in place. Conversely, smear examinationshould be discontinued for the diagnosis of M. tuberculosis infec-
tion and isolation decision; its use should now be limited to
suspected infections with NTM that are not detected by the Xpert
MTB/RIF. Thus, in our hospital, smear examinations are now only
performed in batches once a day (open days) by a group of expert
technicians in the mycobacteria laboratory, as smear examination
remains useful to initiate the microbial diagnosis of infections due
to NTM.
The additional cost for hospitals represented by an Xpert MTB/
RIF-based strategy should be compared to the cost of excessive
isolation due to the poor sensitivity and speciﬁcity of a smear-based
strategy in a low-prevalence country. As reported by Lippincott
et al. [23], an Xpert MTB/RIF-based strategy will improve the ac-
curacy of decisions on airborne isolation, which would lead to a
signiﬁcant reduction of airborne isolation of patients with sus-
pected tuberculosis.
A limitation of our analysis is that during the study period the
Xpert MTB/RIF was mainly dedicated to patients with a high pretest
probability of pulmonary tuberculosis or with suspected MDR
tuberculosis in order to rapidly guide isolation decision. As a
consequence, we report a high rate of culture-conﬁrmed positive
patients (29.3% of the study population) despite the fact that our
study is conducted in a low-prevalence country. Thus, our data,
obtained in a low endemic country (in contrast to previous studies
on the same topic conducted in high-prevalence countries), suggest
that the correlation between quantitative PCR and smear status can
be generalized to any area and certainly to any population. Indeed,
the sensitivity of smear examination may vary between different
laboratories and geographic location, which is unlikely to be the
case for nucleic acid-based methods. In any case, the deﬁnition of
low- and high-prevalence countries based on geographical borders
is seriously challenged by current population migrations, which
might lead to the presence of high-risk groups in historically low-
Fig. 2. Proposed work ﬂow for pulmonary tuberculosis diagnosis based on molecular point-of-care test.
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ducted so far on PCR-based diagnosis of pulmonary tuberculosis is
the dependence on smear microscopy to address the transmission
potential of infected patients. A breakthrough study would deﬁne
the direct relationship between M. tuberculosis DNA load and pa-
tients' infectious potential.
On the basis of our study and on previous studies addressing the
clinical performance and the cost-effectiveness of the Xpert MTB/
RIF, and to follow theWorld Health Organization recommendations
to use the Xpert MTB/RIF as ﬁrst-line test to initiate pulmonary
tuberculosis diagnosis [1], the diagnostic work ﬂow of pulmonary
tuberculosis has been adapted in our hospital (Fig. 2). Patients with
a signiﬁcant pretest probability of pulmonary tuberculosis (clinical
presentation, epidemiology) are isolated. The microbial diagnostic
is initiated by the Xpert MTB/RIF performed in the microbiology
laboratory on spot sputum samples. A negative result does not rule
out an infection but suggests a limited infectious potential of the
patient. An individual evaluation by a pneumology specialist and/or
an infectious disease specialist will then assess the need to main-
tain isolation and the need for a second Xpert MTB/RIF to increase
the sensitivity of the analysis [2]. A third Xpert MTB/RIF has a
limited impact on the sensitivity and NPV of the molecular POCT
[2]. Nevertheless, an additional respiratory specimen might be
collected for a third mycobacterial culture because culture remains
the most sensitive assay and a third sample might help identify a
few additional cases. This work ﬂow takes advantage of the
increased sensitivity and speciﬁcity of the Xpert MTB/RIF but also
takes into consideration the fact that culture remains the most
sensitive method.
Our study demonstrates that an Xpert MTB/RIF-based strategy is
more efﬁcient than smear-dependent strategies for both tubercu-
losis diagnosis and initial evaluation of patient infectiousness.Acknowledgements
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